Pulmonary Arterial Hypertension Stocks List

Pulmonary Arterial Hypertension Stocks Recent News

Date Stock Title
May 31 ASND If You Invested $100 In This Stock 15 Years Ago, You Would Have $4,100 Today
May 31 LQDA Liquidia surges after United Therapeutics request for preliminary injunction denied
May 31 GILD Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal
May 31 GILD Gilead's Trodelvy falls short in significantly improving overall survival in NSCLC
May 31 GILD EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024
May 31 GILD Gilead’s Trodelvy misses goal in bladder cancer study
May 31 GILD Gilead’s Phase III urothelial cancer trial fails to meet primary endpoint
May 30 GILD Gilead's Trodelvy misses primary endpoint in phase 3 bladder cancer trial
May 30 GILD Gilead Provides Update on Phase 3 TROPiCS-04 Study
May 30 GYRE Gyre Therapeutics files to sell 1.08M shares of common stock for holders
May 30 GYRE Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
May 30 ASND Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024
May 29 RVPH Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
May 29 GILD Buy Low, Hold Long: 2 Crushed Dividend Stocks To Buy For High Yields And Long-Term Gains
May 29 LQDA Liquidia Corporation to Present at the 2024 Jefferies Global Healthcare Conference
May 29 GILD Gilead and Cartography enter deal to develop cancer therapies
May 28 GYRE Gyre Therapeutics announces expected addition to Russell 2000 and Russell 3000 Indexes
May 28 GYRE Gyre Therapeutics Announces Expected Addition to the Russell 2000® and Russell 3000® Indexes
May 28 GILD Gilead Sciences: Seriously Undervalued At Peak Pessimism
May 28 GILD Gilead partnering with Cartography Biosciences to discover cancer therapies
Pulmonary Arterial Hypertension

Pulmonary hypertension (PH or PHTN) is a condition of increased blood pressure within the arteries of the lungs. Symptoms include shortness of breath, syncope, tiredness, chest pain, swelling of the legs, and a fast heartbeat. The condition may make it difficult to exercise. Onset is typically gradual.The cause is often unknown. Risk factors include a family history, prior blood clots in the lungs, HIV/AIDS, sickle cell disease, cocaine use, COPD, sleep apnea, living at high altitudes, and problems with the mitral valve. The underlying mechanism typically involves inflammation of the arteries in the lungs. Diagnosis involves first ruling out other potential causes.There is no cure. Treatment depends on the type of disease. A number of supportive measures such as oxygen therapy, diuretics, and medications to inhibit clotting may be used. Medications specifically for the condition include epoprostenol, treprostinil, iloprost, bosentan, ambrisentan, macitentan, and sildenafil. A lung transplant may be an option in certain cases.While the exact frequency of the condition is unknown, it is estimated that about 1,000 new cases occur a year in the United States. Females are more often affected than males. Onset is typically between 20 and 60 years of age. It was first identified by Ernst von Romberg in 1891.

Browse All Tags